Metabolic 1: Introduction to Hepatology Flashcards

1
Q

Abnormal liver tests: acute

A

6 weeks

Drugs

Viral hepatitis (A,B,C,E)

Autoimmune hepatitis

Wilson’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Abnormal liver tests: subacute

A

6-28 weeks

Drugs

Viral hepatitis (A,B,C)

Autoimmune hepatitis

Wilson’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Abnormal liver tests: chronic

A

> 26 weeks

Viral hepatitis (B,C)

Alcohol

NAFLD

Autoimmune hepatitis

Wilson’s disease

Hemochromatosis

A1 antitrypsin deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Assessment of liver function

A

Blood tests: basic liver panel

Liver screen for all causes of liver disease

Imaging

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Liver tests

A

Bilirubin (17umol/l)

Liver enzymes

  • asparate aminotransferase (40io/l)
  • alanine aminotransferase (40iu/l)
  • alkaline phosphatase (200iu/l)
  • gamma GT (50iu/l)

Albumin (40 gm/l)

Prothrombin time

INR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Abnormal LFT’s: liver screen

A

Hepatitis serology: hepatitis A IgM, hepatitis B surface antigen, hepatitis C antibody, hepatitis E IgG and IgM

ANA, SMA LKM (for autoimmune hepatitis)

AMA (for primary biliary cholangitis)

Alpha 1 antitrypsin

Copper, caeruloplasmin (Wilson’s disease)

Ferritin (genetic haemochomatosis)

Ultrasound

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Abnormal liver tests: hepatic

A

Viral hepatitis A,B,C,E

Drug induced liver injury

AUtoimmune hepatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Abnormal liver tests: cholestatic

A

Biliary obstruction

Viral hepatitis A,B,E

DILI

Autoimmune hepatitis

Primary biliary cirrhosis cholangitis (more women)

Primary sclerosing cholangitis (more men)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cirrhosis

A

Generally irreversible chronic liver disease

Increase pressure in the portal circulation, also known as portal hypertension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Liver failure: development of coagulatory and encephalopathy

A

Acute: within 4 weeks

Subacute: between 4-12 weeks

Acute on chronic: in setting of underlying chronic liver disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

In acute liver failure

A

No pre-existing liver disease

Coagulopathy

Confusion (hepatic encephalopathy)

Jaundice

Abnormal liver tests

Cerebral oedema

Increased risk of infections

Renal failure (hepatorenal syndrome)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

In cirrhosis

A

Portal hypertension

  • varices
  • ascites
  • hepatic encephalopathy

Jaundice

Spiders

Enlarged spleen/ pancytopenis

Renal failure

Hepatocellular cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Stage 1 cirrhosis

A

Compensated without varices

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Stage 2 cirrhosis

A

Compensated with varices

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Stage 3 cirrhosis

A

Decompensated with ascites without variceal hemorrhage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Stage 4 cirrhosis

A

Decompensated with/out ascites with variceal hemorrhage

17
Q

Ascites management in cirrhosis

A

Salt restriction

Fluid restriction if low sodium

Diuretics (spironolactone and frusemide)

Large volume paracentesis with albumin cover

If refractory ascites

  • recurrent LVP
  • transjugular intrahepatic portosystemic shunt
  • consider liver transplant
  • long term drains
18
Q

Variceal bleed

A

Haemodynamically stable, correct coagulopathy and thrombocytopenia

IV terlipressin and IV antibiotics

Endoscopy in theatre with anaesthetist present- variceal banding

If blood bath- ballon tamponade

Non selective B blockers for secondary prophylaxis

19
Q

Hepatorenal syndrome (AKI)

A

Functional and fairly rapid renal impairment due to reduced renal perfusion

Increase in serum creatinine by 50% from baseline within 3 months

Type 1 and 2

Treat underlying cause, terlipressin

Liver transplant

20
Q

Hepatic encephalopathy

A

Elevated ammonia

Diagnosis of exclusion

Treat precipitating cause: constipation, diuretics, infection, sedatives, GI bleed

Lactulose

Non absorbable antibiotics

21
Q

Paracetamol overdose

A

Present with nausea, vomiting, RUQ pain, confusion

Jaundice and liver failure usually develops after 3-4 days

Very high liver enzymes and prothrombin time

If receive N acetyl cysteine within 16 hours liver failure rare

Some benefit of NAC even up to 36 hours

In severe cases liver transplant only option

22
Q

Severe alcoholic hepatitis

A

Most serious form of alcohol related injury

Characterised by jaundice and coagulopathy

In patient untreated mortality 40%

Various prognostic scores

Treatment: steroids and pentoxyfilline

23
Q

Risk factors for hepatitis C virus

A

Recipients of clotting factors made before 1987

Injection drug use

Long term haemodialysis

Individuals with multiple sex partners

Recipients of blood transfusions prior to July 1992

Infants born to infected women

24
Q

Factors associated with disease progression of hepatitis C

A

Alcohol consumption

  • 30g/day in men
  • 20g/day in women

Disease acquisition at >40 years

Male gender

HIV coinfection

Hepatitis B virus coinfection

Immunosuppression

25
Q

Hepatitis C: natural history

A

Normal liver&raquo_space;

Acute infection&raquo_space;

Chronic infection develops in 80%&raquo_space;

Chronic hepatitis&raquo_space;

Cirrhosis develops in 20%&raquo_space;

Risk of carcinoma, 1-4% per year

26
Q

Non alcoholic fatty liver disease

A

Resemble alcoholic liver disease but occur in absence of alcohol abuse

usually associated with metabolic syndrome: type 2 DM, obesity, HTN, and elevated TG

Underlying mechanism is insulin resistance

27
Q

Indications for liver transplant in cirrhosis

A

Ascites/ SBP

Variceal bleeding

Hepatic encephalopathy

Hepatocellular cancer